ARCHIVES

Study: Oncotype DX Score Can Predict Local Recurrence

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

Recommendation By Patients; report Of Protocol Committee

August 9, 1996

No Evidence Of Fraud Found In NCI Audit Of NSABP Trials

April 29, 1994

DCT Board Restores Funding to Rosenberg’s Lymphocyte Projects

June 17, 1994

The White House: President’s Proclamation For Breast Cancer Awareness Month

October 9, 1998

Screening Guidelines Differ Among Major Medical Organizations

January 16, 1998